Matt Hewitt
Stock Analyst at Craig-Hallum
(4.23)
# 502
Out of 4,761 analysts
41
Total ratings
57.14%
Success rate
15.34%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLOV Clover Health Investments | Initiates: Buy | $6 | $4.40 | +36.36% | 1 | Dec 17, 2024 | |
| CSBR Champions Oncology | Maintains: Buy | $6 → $8 | $10.17 | -21.34% | 3 | Dec 12, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $26.67 | +19.99% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $39.72 | +61.13% | 6 | Oct 31, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $135 → $140 | $120.67 | +16.02% | 3 | Jul 9, 2024 | |
| SLP Simulations Plus | Reiterates: Buy | $56 | $31.77 | +76.27% | 7 | Jul 3, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $4.06 | +146.31% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $22.64 | +32.51% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $3.85 | +81.82% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $158.99 | +25.79% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.65 | +173.97% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $11.51 | +160.64% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.74 | +22,888.51% | 1 | Jan 4, 2022 |
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $4.40
Upside: +36.36%
Champions Oncology
Dec 12, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $10.17
Upside: -21.34%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $26.67
Upside: +19.99%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $39.72
Upside: +61.13%
Ligand Pharmaceuticals
Jul 9, 2024
Maintains: Buy
Price Target: $135 → $140
Current: $120.67
Upside: +16.02%
Simulations Plus
Jul 3, 2024
Reiterates: Buy
Price Target: $56
Current: $31.77
Upside: +76.27%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $4.06
Upside: +146.31%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $22.64
Upside: +32.51%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $3.85
Upside: +81.82%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $158.99
Upside: +25.79%
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $3.65
Upside: +173.97%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $11.51
Upside: +160.64%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $1.74
Upside: +22,888.51%